23andMe AI Visibility Market Strategy Report - DNA Testing Kits

Answer Capsule

23andMe holds the second-strongest recommendation position in the DNA testing kits category for October 2026, with valid recommendation coverage of 67.32% and a raw mention presence rate of 97.16%. The brand is visible in nearly every qualified AI response but converts that presence into a first-position recommendation in only 1.60% of observations, a gap that defines its competitive position. Its clearest win is a 2.20-point month-over-month coverage gain from September to October 2026, the largest upward move of any tracked brand. Its clearest weakness is a top-three rate that fell 5.90 points from the July 2026 baseline to 61.63%, and its clearest opportunity is closing the distance between broad presence and first-position recommendation strength.

Who This Report Is For

This report is written for 23andMe's marketing, communications, and product leadership teams, and for category analysts tracking how AI search and chat surfaces present consumer DNA testing brands during the discovery and consideration stage.

Report Card

Executive Summary

23andMe enters October 2026 as the second-ranked brand in the DNA testing kits category by valid recommendation coverage, at 67.32%. That figure sits 5.90 percentage points behind category leader AncestryDNA at 73.18% and 7.82 points ahead of third-place MyHeritage DNA at 59.50%. The brand is mentioned in 97.16% of qualified observations, which places it alongside AncestryDNA at the top of the category for raw mention presence.

The gap between presence and recommendation is the defining feature of 23andMe's position. The brand appears in nearly every qualified response but receives a valid recommendation in roughly two of every three. Its top-three rate of 61.63% and its rank-one rate of 1.60% diverge sharply, meaning 23andMe is frequently shortlisted but almost never placed first.

The strongest platform signal for 23andMe is ChatGPT, where it holds a valid recommendation coverage of 84.06% and a top-three rate of 79.71%. Perplexity is the second-strongest surface at 77.59% coverage. The weakest platform signal is AI Mode, where coverage falls to 51.16% and the top-three rate to 46.51%, the lowest of any tracked surface for the brand.

The strongest cluster is the only qualified cluster in the public benchmark, Brand Recommendation, which captures discovery and consideration intent. The benchmark contains no qualified observations in the Pricing and Value or Multi-Brand Comparison clusters, so the public data cannot speak to how AI systems position 23andMe on price or in head-to-head comparisons.

Sentiment framing is positive overall, with 397 positive mentions, 140 neutral mentions, and 10 negative mentions across 547 present observations. The net sentiment score of 0.7075 is the second-lowest among the top four brands, behind AncestryDNA, MyHeritage DNA, and FamilyTreeDNA.

The clearest opportunity for 23andMe is converting its near-universal presence into first-position recommendations. The brand already appears in almost every relevant AI response; the work ahead is about what those responses say when they place it.

What 23andMe Is Winning

Questions This Section Answers

• Which AI platform gives 23andMe its strongest recommendation signal?
• How did 23andMe's recommendation coverage move from September to October 2026?

23andMe holds the second-strongest recommendation position in the category. Its valid recommendation coverage of 67.32% places it ahead of every tracked brand except AncestryDNA, and its valid recommendation count of 379 is the second-highest in the dataset.

The brand recorded the largest upward month-over-month move of any tracked company, rising 2.20 points from 65.10% in September 2026 to 67.32% in October 2026. That move followed two consecutive monthly declines and remains within normal month-to-month variation, but it is the only positive directional signal at the top of the category this month.

ChatGPT is 23andMe's strongest surface. The brand holds a valid recommendation coverage of 84.06% and a top-three rate of 79.71% on that platform, with 58 valid recommendations and 55 top-three placements across 69 observations. Perplexity follows at 77.59% coverage and a 75.86% top-three rate.

23andMe's raw mention presence rate of 97.16% is effectively tied with AncestryDNA's 99.64% at the top of the category. The brand is not struggling to be seen; it is struggling to be placed first.

Where 23andMe Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does 23andMe's 97.16% presence rate not translate into first-position recommendations?
• Which platform shows the weakest recommendation conversion for 23andMe?
• Where are 23andMe's negative mentions concentrated?

The clearest gap is between presence and first-position recommendation. 23andMe appears in 97.16% of qualified observations but is the first-listed recommendation in only 1.60% of them, a rank-one count of 9 placements against 347 top-three placements. AncestryDNA, by contrast, holds a rank-one rate of 69.63% with 392 first-position placements. The two brands carry similar overall coverage, but their first-position strength is not comparable.

The top-three rate has also weakened across the series. 23andMe's top-three rate fell 5.90 points from 67.50% in July 2026 to 61.63% in October 2026, a decline the benchmark classifies as significant. Top-three placements fell from 401 in July to 347 in October, even as the qualified observation set contracted by only 31 observations. The brand is being placed lower within recommendations more often than it was at baseline.

AI Mode is the weakest platform for 23andMe. Coverage on that surface sits at 51.16%, well below the brand's category-wide figure, and the top-three rate is 46.51%. The platform also carries the highest neutral mention share for the brand at 39.53%, suggesting 23andMe is frequently referenced on AI Mode without being recommended.

The negative mention profile is concentrated. Of the 10 negative mentions recorded for 23andMe across the category, 7 appear on Copilot. No other platform records more than 2 negative mentions for the brand. This is a small absolute count, but the concentration is notable given that Copilot also carries the lowest net sentiment score for 23andMe at 0.6951.

Biggest Opportunity

Questions This Section Answers

• What is the single largest opportunity for 23andMe in AI recommendations?
• Why is 23andMe's problem a recommendation-conversion issue rather than a visibility issue?

The single largest opportunity for 23andMe is closing the gap between its 97.16% presence rate and its 1.60% rank-one rate. The brand is already in the room for nearly every high-intent discovery question in the category. The work is about what AI systems say when they place it.

This is a recommendation-conversion problem, not a visibility problem. The prompts driving the category are discovery and consideration questions such as which DNA test is best for ancestry, which kit is most accurate, and which company is most reliable. 23andMe is present in nearly all of them. The opportunity is to strengthen the public evidence layer that AI systems draw on when they decide which brand to list first, particularly on AI Mode and Copilot, where the brand's recommendation strength lags its category-wide position.

Competitive Landscape

Questions This Section Answers

• How does 23andMe's rank-one rate compare to AncestryDNA's?
• Which brands sit closest to 23andMe in the DNA testing kits recommendation standings?

AncestryDNA holds the strongest recommendation-stage position in the DNA testing kits category, with 23andMe as the clear second and MyHeritage DNA as the strongest challenger below the top two. Recommendation strength drops sharply after the top four brands.

Average recommended rank covers rank-eligible recommendations only.

23andMe sits second in the table on top-three rate and second on average recommended rank, but its rank-one rate of 1.60% is closer to the mid-tier brands than to the category leader. The table shows a brand with strong shortlist presence and weak first-position strength relative to its overall standing.

AI Response Inconsistency Alerts

Questions This Section Answers

• What corporate-status claims about 23andMe conflict across AI platforms?
• Which AI platforms disagree most about 23andMe's reliability and accuracy?

Ten critical and high-severity factual inconsistencies were detected for 23andMe across seven AI platforms: ChatGPT, Copilot, Gemini, AI Mode, AI Mode keyword surfaces, AI Overviews, and AI Overviews keyword surfaces. Nine of the ten conflicts concern the brand's corporate status, and one concerns pricing. All ten carry a confidence score of 0.85 or higher.

The most consequential conflict concerns whether 23andMe filed for Chapter 11 bankruptcy. When asked which is the best DNA kit for ancestry, AI Mode stated that corporate stability and privacy changes have been under scrutiny due to recent corporate restructurings, with no mention of bankruptcy, citing Wirecutter, CNET, and Genomelink. ChatGPT, answering the same question, stated that 23andMe filed for Chapter 11 bankruptcy in 2025, citing Reuters and a comparison page. The two responses describe incompatible corporate states.

A second critical conflict concerns whether 23andMe is still a reliable provider. When asked what the most reliable DNA testing company is, Gemini described 23andMe as the gold standard for health and wellness insights and recommended it as a reliable company, citing Genealogy Explained, Your DNA Guide, and DNA Weekly. Copilot, answering the same question, stated that 23andMe suffered a major data breach and bankruptcy in 2025, raising trust issues, citing Genomelink, Infolabmed, and Yahoo. The flagged source excerpts show Genealogy Explained describing 23andMe as the leader in consumer health testing on one side, and Yahoo stating that 23andMe experienced a data breach, a lawsuit, and eventual bankruptcy and has since been removed from the list on the other.

A third critical conflict concerns accuracy positioning. When asked which DNA website is the most accurate, AI Mode described 23andMe as generally viewed as top-tier and recommended for ethnicity and health reports, with no mention of bankruptcy, citing 23andMe's own ancestry page and Your DNA Guide. Copilot stated that 23andMe went bankrupt in 2025, leaving 15 million users' data in limbo, citing KnowYourDNA and DNA Weekly. The flagged sources include 23andMe's own product page and a KnowYourDNA accuracy ranking on one side, and a Chronos Genomics comparison table noting bankruptcy concerns on the other.

A fourth critical conflict concerns the cheapest alternative to 23andMe. When asked that question, Gemini made no mention of bankruptcy and implied 23andMe is still operating normally, citing a KnowYourDNA budget guide. Copilot, answering the same question and citing the same KnowYourDNA page alongside GuideToGenetics and DNA Weekly, stated that 23andMe went bankrupt in 2025. The flagged sources include a Genobalance buyer's guide stating that 23andMe filed for Chapter 11 in March 2025 after declining sales and a 2023 data breach.

A fifth critical conflict concerns asset ownership. When asked what the best company to get a DNA test from is, ChatGPT stated that 23andMe went through bankruptcy after a 2023 data breach and that its genetic-data assets were sold to TTAM Research Institute, citing Ancestry's privacy page and a Michigan Attorney General press release. Copilot, answering the same question, stated that 23andMe remains the most established option and is still the leader for health and ancestry, citing GuideToGenetics, Verold, and KnowYourDNA. One flagged source, GuideToGenetics, is marked as supporting both sides, containing both the Chapter 11 statement and the claim that 23andMe is still the most established option.

A sixth critical conflict concerns home testing recommendations. When asked what the best DNA test to take at home is, Gemini described 23andMe as an active, recommended health and ancestry DNA testing company, citing Genomelink, DNA Weekly, and Who Do You Think You Are Magazine. Copilot stated that 23andMe had a bankruptcy in 2025, citing KnowYourDNA, GuideToGenetics, and Verold. The flagged sources include a Wellwhisk comparison noting 23andMe's FDA-approved health reports on one side and GuideToGenetics stating that the company is currently marked "verify" because of its 2025 Chapter 11 filing and the ongoing TTAM transition on the other.

A seventh critical conflict concerns the best DNA websites. When asked that question, Copilot stated that 23andMe went bankrupt in 2025 and its future is uncertain, citing GuideToGenetics, Verold, and DNA Weekly. ChatGPT presented 23andMe as a current, active top DNA testing option with no mention of bankruptcy, citing 23andMe's own pages and FamilyTreeDNA. The flagged sources include YouCompare describing 23andMe's FDA-approved health reports as unmatched on one side and Verold describing the bankruptcy as making the question of which kit to trust more urgent on the other.

An eighth high-severity conflict concerns corporate stability in genetic testing. When asked which company is the best for genetic testing, ChatGPT presented 23andMe as a current, recommended option for ancestry plus health reports with no mention of bankruptcy or instability, citing MedlinePlus, Ancestry's accuracy page, and the FDA. Copilot stated that 23andMe underwent bankruptcy restructuring in 2025, so long-term support is less certain, citing GuideToGenetics, OptimizeBiomarkers, and KnowYourDNA.

A ninth high-severity conflict concerns accuracy and market leadership. When asked what DNA test is more accurate, AI Overviews described 23andMe as the market leader for FDA-authorized health reports and presented it as a current, stable, recommended option, citing YouTube reviews and 23andMe's own ancestry page. Copilot stated that 23andMe went through bankruptcy and was acquired, so stability is a consideration, citing KnowYourDNA and a Chronos Genomics comparison table.

A tenth high-severity conflict concerns pricing. When asked how much a DNA test costs, AI Overviews keyword surfaces listed 23andMe Ancestry plus Health at a range of 119 to 229, citing DNA Diagnostics Center and Xcode Life. AI Mode keyword surfaces listed the same product under health and wellness assessments at a range of 100 to 640. The two stated ranges for the same product are incompatible.

Prompt Evidence

ChatGPT / Brand Recommendation Prompt: "What are the best DNA websites?" Result: ChatGPT presented 23andMe as a current, active top DNA testing option with no mention of bankruptcy, citing 23andMe's own pages and FamilyTreeDNA.

Copilot / Brand Recommendation Prompt: "What is the most reliable DNA testing company?" Result: Copilot stated that 23andMe suffered a major data breach and bankruptcy in 2025, raising trust issues, while Gemini answering the same question described the brand as the gold standard for health and wellness insights.

AI Mode / Brand Recommendation Prompt: "Which is the best DNA kit for ancestry?" Result: AI Mode referenced corporate restructurings without mentioning bankruptcy, while ChatGPT answering the same question stated that 23andMe filed for Chapter 11 in 2025.

AI Overviews / Brand Recommendation Prompt: "What DNA test is more accurate?" Result: AI Overviews described 23andMe as the market leader for FDA-authorized health reports and presented it as a current, stable option, while Copilot stated the brand went through bankruptcy and was acquired.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map every high-intent prompt where 23andMe appears but is not recommended first, and identify which competitor takes the first-position slot in each case.

Phase 2: Recommendation Readiness Plan Prioritize the AI Mode and Copilot surfaces, where 23andMe's recommendation strength and sentiment framing lag its category-wide position, and define the correction targets for each.

Phase 3: Owned Answer Layer Buildout Strengthen 23andMe's own pages so that corporate status, product scope, and pricing are stated clearly and consistently, reducing the surface area for conflicting AI synthesis.

Phase 4: Citation and Authority Layer Development Build and reinforce the third-party review, guide, and comparison sources that AI systems cite when they decide which brand to place first, with particular attention to the sources currently producing conflicting corporate-status claims.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track 23andMe's top-three rate, rank-one rate, and sentiment framing month over month across all six surfaces, with the rank-one rate as the primary conversion metric.

Why This Matters

Questions This Section Answers

• What does the gap between 23andMe's presence rate and rank-one rate mean for buyers at the decision moment?
• Why is being mentioned in AI responses not enough for 23andMe to win the recommendation?

AI presence alone is not enough. 23andMe is mentioned in 97.16% of qualified responses in the DNA testing kits category, yet it is the first-listed recommendation in only 1.60% of them. A buyer who asks an AI system which DNA test to take will see 23andMe in the answer, but in most cases the system will place another brand first. Presence without first-position recommendation is visibility that does not convert at the decision moment.

The next move is targeted correction of the prompt, page, and citation layers. The inconsistency data shows that AI systems are synthesizing conflicting claims about 23andMe's corporate status from the same public sources, and that conflict appears in the answers buyers see. Correcting the owned answer layer and reinforcing the third-party sources that AI systems retrieve is the path from being mentioned to being recommended first.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For 23andMe in October 2026, that is (397 × 1 + 140 × 0 + 10 × -1) / 547, which produces a net sentiment score of 0.7075.

This matters because unclassified mention counts are misleading. A brand can appear in nearly every AI response and still lose the recommendation if the framing is neutral, cautionary, or comparative. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal, and counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because it separates being seen from being chosen.

Sentiment by Platform

Methodology

1. This report is a benchmark-based AI Visibility Company Market Strategy Report for 23andMe in the DNA Testing Kits category, produced from the LLM Authority Index AI Visibility Market Discovery Index and the associated CiteWorks Studio analysis for October 2026.
2. The reporting window is October 2026, with baseline comparisons drawn from July 2026 and month-over-month comparisons drawn from September 2026.
3. Six AI and search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The October 2026 measurement produced 563 qualified benchmark observations from a raw collection of 800 prompt-surface observations and 467 unique questions.
5. Ten brands were tracked in the competitor universe: AncestryDNA, 23andMe, African Ancestry, CRI Genetics, FamilyTreeDNA, Health Nucleus, Living DNA, MyHeritage DNA, Nebula Genomics, and tellmeGen.
6. One public high-intent cluster produced qualified observations in October 2026: Brand Recommendation, covering discovery and consideration intent. The Pricing and Value and Multi-Brand Comparison clusters produced no qualified observations in the public benchmark.
7. Stage 0 extraction retained the query, surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources for each observation.
8. A mention is counted when 23andMe appears in a qualified observation in any form, including neutral or cautionary references.
9. A valid recommendation is counted only when the dataset marks the observation as a valid recommendation for 23andMe, with rank credit applied to positive valid recommendations placed first through tenth.
10. Brand-level percentages use the 563 qualified observations as the public denominator, not the 800 raw prompts collected.
11. The public benchmark does not measure market share, attributable sales, organic-search ranking, social mention volume, or causality from a metric movement alone. It records the change; it does not by itself establish why the change occurred.
12. Small-count movement should be read directionally. 23andMe's rank-one count of 9 placements is small enough that a change of a few observations can move the percentage materially.

See How AI Is Recommending Your Brand

The public benchmark shows where 23andMe stands in AI recommendations across the DNA testing kits category. A company-level AI visibility audit maps the specific prompts, surfaces, competitors, ranking patterns, sentiment framing, and evidence sources behind those numbers into a prioritized strategy. It turns the benchmark's "what changed" into an actionable "why and what next."